Combining ACE inhibitors and angiotensin receptor blockers in non-diabetic renal disease

Combination of trandolapril and losartan is effective in postponing the development of end-stage renal failure compared to either drug alone in patients with non-diabetic renal disease.

In the COOPERATE study 336 Japanese patients with non-diabetic renal disease were randomized to receive either a combination of trandolapril 3 mg/d and losartan 100 mg/d, or trandolapril alone, or losartan alone. Ten (11%) of 85 patients on combination treatment reached the combined end point of time to doubling of serum creatinine concentration or end-stage renal disease, compared to 20 (23%) of 85 on trandolapril alone (HR 0.38, 95% CI 0.18 to 0.63) or to 20 (23%) of 86 on losartan alone (HR 0.40, 95% CI 0.17 to 0.69). Frequency of side effects with combination treatment was the same as with trandolapril alone.

Ədəbiyyat

1. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003 Jan 11;361(9352):117-24.